Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
All content for The Oxford Colloquy is the property of Oxford University and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
The Pandemic People: Dame Catherine Elizabeth Bingham
The Oxford Colloquy
51 minutes
2 years ago
The Pandemic People: Dame Catherine Elizabeth Bingham
Kate Bingham, a British venture capitalist, discussed her role in the UK's COVID-19 vaccine rollout and her leadership of the vaccine task force and the importance of diplomacy in the global fight against COVID-19. In this episode of his podcast, Sir Andrew Pollard was joined by Kate Bingham, a venture capitalist where she is currently a managing partner, who played a crucial role in the UK's COVID-19 vaccine rollout. Bingham started by explaining what a venture capitalist does and her background, skills and how she brings in experts to ensure the investments are robust and are there to help when needed.
The conversation then shifted to the COVID-19 pandemic and how Sir Patrick Vallance assembled a team to help with the possible rollout of COVID-19 vaccines. Bingham was recruited to lead the Vaccine Task Force and had to recruit her own team to manage the enormous task ahead. She talked about diplomacy and how they were not competing with any country but rather the COVID-19 virus itself.
The conversation provided an inside look into what was happening within the Vaccine Task Force and the wider team that covered legal and manufacturing aspects. Bingham talked about the deals on the 190 vaccines that were in some level of development in the period of May-June 2020 and how the government made their choices. They had to produce a business case and then picked 10-12 vaccines for COVID-19, looking into the different formats of vaccines. The UK had the first vaccines approved in the world, and Bingham discussed how the UK was ahead of the game. They also discussed how the US worked against the clock for vaccine rollouts and how they used teamwork to work together.
The conversation then delved into which vaccine would be the most promising and what data was available, focusing on the science and clinical aspects in the fast-paced time of the pandemic. Bingham talked about the technical issues they faced and how important timing was for the Vaccine Task Force.
She also discussed whether she would have done things differently within her team during the peak of the COVID-19 pandemic and how she would push harder if given the chance. They talked about the importance of building relationships with each manufacturer of the vaccines, being ready for other strains of the virus, affordability, and pushing forward to secure vaccines and act to be ready if this happens again.
Bingham also talked about the relationship between her team, the media, and the government during the peak of the pandemic and the issues they could have faced. She discussed how they got things done under the radar.
Overall, the conversation provided a fascinating insight into the behind-the-scenes work that went into the COVID-19 vaccine rollout in the UK, highlighting the importance of teamwork, diplomacy, and building relationships to achieve a common goal. It also shed light on the challenges and technical issues faced during the pandemic and the importance of being ready for future outbreaks.
Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
The Oxford Colloquy
Professor Peter Openshaw discusses Respiratory Syncytial Virus Infection (RSV). RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it is the leading cause of hospitalisation in babies Step into the world of groundbreaking medical research with the latest episode of our podcast as Sir Andrew Pollard engages in a riveting conversation with the esteemed Professor Peter Openshaw from Imperial University. Peter Openshaw is a respiratory physician and mucosal immunologist researcher, studying how the immune system both protects against viral infection but also causes disease. He has run studies of human experimental infection of volunteers since 2008 and is Director of the HIC-Vac consortium established to accelerate vaccine development for pathogens of high global impact.
Delving deep into the realm of Respiratory Syncytial Virus (RSV) infection, this episode unveils the complexities of a common respiratory virus that can escalate into a serious health concern. RSV is a common respiratory virus that usually causes mild, cold-like symptoms in most adults but it can become more severe and it is the leading cause of hospitalisation in babies.
In this illuminating dialogue, listeners are treated to a comprehensive exploration of RSV, from its seemingly innocuous cold-like symptoms to its potential for severe illness, particularly in vulnerable populations. The conversation navigates through Professor Openshaw's early investigations into immune responses, his fascination with inflammatory reactions, and the transformative advancements witnessed in RSV medical research over the years.
As the episode progresses, attention turns to the horizon of medical innovation, with a thoughtful examination of the challenges inherent in vaccine trials and the tantalising prospect of novel treatments for infectious diseases like RSV. Join Sir Andrew Pollard and Professor Peter Openshaw as they peer into the future, offering a glimpse of what lies ahead in the relentless pursuit of conquering respiratory ailments. Creative Commons Attribution-Non-Commercial-Share Alike 2.0 UK: England & Wales; http://creativecommons.org/licenses/by-nc-sa/2.0/uk/
